Rationale for the rational development of new cardiac imaging agents

Research output: Contribution to journalReview article

Abstract

There are several prerequisites for the development of new diagnostic cardiovascular radiopharmaceuticals. Agents which are proposed for clinical use must offer significant advantages in one or more of the following categories: I) Radiopharmacy [dosimetry, dose preparation, dose availability]; II) Imaging characteristics [spatial and temporal resolution, radiotracer biokinetics, patient throughput and acquisition protocols]; and III) Measurement of a previously unmeasurable physiologic or pharmacologic event [metabolic pathways, receptors, neural pathways, preclinical disease]. Technetium-99m-based radiopharmaceuticals are particularly attractive, in view of their excellent characteristics for imaging with the Anger gamma camera. In addition, the increasing use of tomographic imaging and reconstruction techniques has magnified the importance of developing radiotracers with minimal soft tissue attenuation effects. Technetium-99m and positron emitting radioisotopes offer this advantage. A wide choice of biologically and pharmacologically relevant ligands are available for complexing with these radiotracers. The clinical studies are underway in order to validate these new agents, and to determine their value in the modern practice of nuclear medicine. Technetium-99m sestamibi is just one example of a novel radiotracer with improved imaging characteristics that has undergone careful pre-clinical and clinical testing, and which has emerged as a useful diagnostic imaging agent. Future studies should be directed towards the development of tracers with well-defined biokinetic characteristics, which are advantageous for tomographic imaging. The future applications of tracer imaging techniques for the pre-clinical diagnosis of cardiovascular, oncologic and other medical conditions are significant and are expanding. Combined diagnostic and therapeutic approaches may eventually be possible with a single injection of a pharmacologically active radiotracer.

Original languageEnglish (US)
Pages (from-to)207-214
Number of pages8
JournalAnnals of Nuclear Medicine
Volume7
Issue number4
DOIs
StatePublished - Dec 1 1993
Externally publishedYes

Fingerprint

Radiopharmaceuticals
Technetium
Technetium Tc 99m Sestamibi
Neural Pathways
Gamma Cameras
Nuclear Medicine
Anger
Diagnostic Imaging
Metabolic Networks and Pathways
Radioisotopes
Electrons
Ligands
Injections
Therapeutics
Clinical Studies

Keywords

  • atherosclerosis
  • myocardial perfusion
  • positron emission tomography
  • radionuclide imaging
  • receptors

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Rationale for the rational development of new cardiac imaging agents. / Miller, Donald D.

In: Annals of Nuclear Medicine, Vol. 7, No. 4, 01.12.1993, p. 207-214.

Research output: Contribution to journalReview article

@article{61a21f35199c44809b978fb38999911a,
title = "Rationale for the rational development of new cardiac imaging agents",
abstract = "There are several prerequisites for the development of new diagnostic cardiovascular radiopharmaceuticals. Agents which are proposed for clinical use must offer significant advantages in one or more of the following categories: I) Radiopharmacy [dosimetry, dose preparation, dose availability]; II) Imaging characteristics [spatial and temporal resolution, radiotracer biokinetics, patient throughput and acquisition protocols]; and III) Measurement of a previously unmeasurable physiologic or pharmacologic event [metabolic pathways, receptors, neural pathways, preclinical disease]. Technetium-99m-based radiopharmaceuticals are particularly attractive, in view of their excellent characteristics for imaging with the Anger gamma camera. In addition, the increasing use of tomographic imaging and reconstruction techniques has magnified the importance of developing radiotracers with minimal soft tissue attenuation effects. Technetium-99m and positron emitting radioisotopes offer this advantage. A wide choice of biologically and pharmacologically relevant ligands are available for complexing with these radiotracers. The clinical studies are underway in order to validate these new agents, and to determine their value in the modern practice of nuclear medicine. Technetium-99m sestamibi is just one example of a novel radiotracer with improved imaging characteristics that has undergone careful pre-clinical and clinical testing, and which has emerged as a useful diagnostic imaging agent. Future studies should be directed towards the development of tracers with well-defined biokinetic characteristics, which are advantageous for tomographic imaging. The future applications of tracer imaging techniques for the pre-clinical diagnosis of cardiovascular, oncologic and other medical conditions are significant and are expanding. Combined diagnostic and therapeutic approaches may eventually be possible with a single injection of a pharmacologically active radiotracer.",
keywords = "atherosclerosis, myocardial perfusion, positron emission tomography, radionuclide imaging, receptors",
author = "Miller, {Donald D}",
year = "1993",
month = "12",
day = "1",
doi = "10.1007/BF03164700",
language = "English (US)",
volume = "7",
pages = "207--214",
journal = "Annals of Nuclear Medicine",
issn = "0914-7187",
publisher = "Springer Japan",
number = "4",

}

TY - JOUR

T1 - Rationale for the rational development of new cardiac imaging agents

AU - Miller, Donald D

PY - 1993/12/1

Y1 - 1993/12/1

N2 - There are several prerequisites for the development of new diagnostic cardiovascular radiopharmaceuticals. Agents which are proposed for clinical use must offer significant advantages in one or more of the following categories: I) Radiopharmacy [dosimetry, dose preparation, dose availability]; II) Imaging characteristics [spatial and temporal resolution, radiotracer biokinetics, patient throughput and acquisition protocols]; and III) Measurement of a previously unmeasurable physiologic or pharmacologic event [metabolic pathways, receptors, neural pathways, preclinical disease]. Technetium-99m-based radiopharmaceuticals are particularly attractive, in view of their excellent characteristics for imaging with the Anger gamma camera. In addition, the increasing use of tomographic imaging and reconstruction techniques has magnified the importance of developing radiotracers with minimal soft tissue attenuation effects. Technetium-99m and positron emitting radioisotopes offer this advantage. A wide choice of biologically and pharmacologically relevant ligands are available for complexing with these radiotracers. The clinical studies are underway in order to validate these new agents, and to determine their value in the modern practice of nuclear medicine. Technetium-99m sestamibi is just one example of a novel radiotracer with improved imaging characteristics that has undergone careful pre-clinical and clinical testing, and which has emerged as a useful diagnostic imaging agent. Future studies should be directed towards the development of tracers with well-defined biokinetic characteristics, which are advantageous for tomographic imaging. The future applications of tracer imaging techniques for the pre-clinical diagnosis of cardiovascular, oncologic and other medical conditions are significant and are expanding. Combined diagnostic and therapeutic approaches may eventually be possible with a single injection of a pharmacologically active radiotracer.

AB - There are several prerequisites for the development of new diagnostic cardiovascular radiopharmaceuticals. Agents which are proposed for clinical use must offer significant advantages in one or more of the following categories: I) Radiopharmacy [dosimetry, dose preparation, dose availability]; II) Imaging characteristics [spatial and temporal resolution, radiotracer biokinetics, patient throughput and acquisition protocols]; and III) Measurement of a previously unmeasurable physiologic or pharmacologic event [metabolic pathways, receptors, neural pathways, preclinical disease]. Technetium-99m-based radiopharmaceuticals are particularly attractive, in view of their excellent characteristics for imaging with the Anger gamma camera. In addition, the increasing use of tomographic imaging and reconstruction techniques has magnified the importance of developing radiotracers with minimal soft tissue attenuation effects. Technetium-99m and positron emitting radioisotopes offer this advantage. A wide choice of biologically and pharmacologically relevant ligands are available for complexing with these radiotracers. The clinical studies are underway in order to validate these new agents, and to determine their value in the modern practice of nuclear medicine. Technetium-99m sestamibi is just one example of a novel radiotracer with improved imaging characteristics that has undergone careful pre-clinical and clinical testing, and which has emerged as a useful diagnostic imaging agent. Future studies should be directed towards the development of tracers with well-defined biokinetic characteristics, which are advantageous for tomographic imaging. The future applications of tracer imaging techniques for the pre-clinical diagnosis of cardiovascular, oncologic and other medical conditions are significant and are expanding. Combined diagnostic and therapeutic approaches may eventually be possible with a single injection of a pharmacologically active radiotracer.

KW - atherosclerosis

KW - myocardial perfusion

KW - positron emission tomography

KW - radionuclide imaging

KW - receptors

UR - http://www.scopus.com/inward/record.url?scp=0027145525&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027145525&partnerID=8YFLogxK

U2 - 10.1007/BF03164700

DO - 10.1007/BF03164700

M3 - Review article

C2 - 8292445

AN - SCOPUS:0027145525

VL - 7

SP - 207

EP - 214

JO - Annals of Nuclear Medicine

JF - Annals of Nuclear Medicine

SN - 0914-7187

IS - 4

ER -